Clinical trial
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus…
NCT02864251 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT02864251 |
|---|---|
| Title | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy |
| Official title | Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR… |
| Acronym | CheckMate722 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Ono Pharmaceutical Co. Ltd Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Biological, Drug |
| Interventions | Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin |
| Enrollment | 367 |
| Start date | Mar 17, 2017 |
| Primary completion | Jan 20, 2022 |
| Completion | Oct 17, 2022 |
| First posted | Aug 11, 2016 |
| Last update posted | Sep 28, 2023 |
| Countries | Canada, China, France, Hong Kong, Japan, Singapore, South Korea, Spain, Taiwan, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: